Overview

Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer

Status:
Recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
This research study is comparing two standard of care treatment options based on blood test results for participants who have metastatic colorectal cancer. The names of the potential treatments involved in this study are: - Active surveillance - FOLFIRI treatment - Nivolumab treatment - Encorafenib/Binimetinib/Cetuximab treatment
Phase:
Phase 3
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborator:
Stand Up To Cancer
Treatments:
Camptothecin
Cetuximab
Fluorouracil
Irinotecan
Leucovorin
Nivolumab